Navigation Links
Algeta and Lumiphore Announce Global Agreement for the Development of Targeted Alpha-Pharmaceutical Therapeutics
Date:10/21/2010

RICHMOND, Calif., Oct. 21 /PRNewswire/ -- Lumiphore Inc., a biotechnology leader in new proprietary bifunctional metal-chelation technology for use in high-value imaging, diagnostics, and therapeutics and Algeta ASA (OSE:ALGETA), the cancer therapeutics company, announced that they have signed a global agreement on incorporation of Lumiphore's Lumi4® complexes in Algeta's targeted radiotherapeutics and companion diagnostics.

Under the agreement, Algeta has an option to the exclusive rights to incorporate Lumi4® isophthalamide chelation technology into future targeted radiopharmaceutical therapeutics for cancer.

"Lumiphore's goal is to bring the benefits of bifunctional metal-chelation technology to therapeutic markets that use targeted radiopharmaceuticals to treat cancer. The ability to chelate radioactive metal isotopes and covalently attach them to therapeutic antibodies, peptides, proteins, or other receptor targeting molecules will benefit targeted delivery to cancer sites and has the potential to make current therapeutic antibodies more effective," said Dr. Ken Raymond, President and CEO of Lumiphore.

Algeta has proprietary technology relating to the use of the alpha emitter thorium-227 to protein/peptides to target specific cancer cells. Thorium-227 is an isotope that emits high-energy alpha particles. Such isotopes are of considerable interest in the treatment of cancer as they are potent at killing tumor cells but have a highly localized effect. By linking thorium-227 to tumor-targeting molecules such as monoclonal antibodies, Algeta has the potential to create a pipeline of new generation alpha-pharmaceuticals designed to specifically seek and destroy cancers while minimizing damage to surrounding healthy tissues. "Using Lumi4® bifunctional chelates," explained Thomas Ramdahl, Chief Technology Officer of Algeta, "could create a new class of radioimmunotherapeutics. By linking thorium-227 to selected tumor targeting an
'/>"/>

SOURCE Lumiphore, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
2. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
3. Boston Scientific Announces FDA Clearance and CE Mark Approval for Advanix™ Biliary Stents
4. Celtic Pharma Announces Issuance of U.S. Patent 7,816,323 for Xerecept® in Combination with Avastin® as a Treatment for Breast and Colon Cancers
5. Hanger Orthopedic Group, Inc. Announces Pricing of $200 Million of Senior Notes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter and Nine-Months Ended September 30, 2010 and Declares Quarterly Dividend
7. K-V Pharmaceutical Company Announces Establishment of New Generic Marketing Subsidiary and Senior Executive Appointment
8. Endo Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 1, 2010
9. MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
10. Amgen Announces Webcast of 2010 Third Quarter Financial Results
11. ERT to Announce Third Quarter 2010 Results on November 4, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... LAKE, N.J. and SAN DIEGO ... Inc. (NASDAQ: ARNA ) announced today that an ... 3 trials of lorcaserin entitled, "Early Weight Loss While on ... Weight-Loss Outcomes," was recently published in the online issue of ... Obesity Society. The objective of these analyses was to identify ...
(Date:7/30/2014)... DALLAS , July 30, 2014 /PRNewswire-iReach/ -- ... on Global and Chinese Heparin sodium (CAS 9041-08-1) ... reviews the basic information of Heparin sodium (CAS ... application and manufacturing technology. The report then explores ... (CAS 9041-08-1) & calcium (CAS 37270-89-6) listing their ...
(Date:7/30/2014)...   Epic Sciences, Inc. ("Epic"), a ... novel diagnostics to personalize and advance the treatment ... of a $30 million Series C Preferred Stock ... and Arcus Ventures, existing investors Domain Associates, Roche ... as undisclosed individual investors. With the proceeds of ...
Breaking Medicine Technology:Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3
... NASHVILLE, Tenn., May 11, 2011 Cumberland Pharmaceuticals ... pharmaceutical company focused on hospital acute care and gastroenterology ... overview at the 2011 UBS Global Specialty Pharmaceuticals Conference ... p.m. The presentation will be simultaneously ...
... S.C., May 11, 2011 /PRNewswire-USNewswire/ -- ... announced that two client companies received big check investment ... Therapeutics and EnviroMix, both technology-based start-ups located in the ... technology and business model. Madeira Therapeutics was ...
Cached Medicine Technology:SC Launch Presents "Big Check" Investment to Two South Carolina Companies 2SC Launch Presents "Big Check" Investment to Two South Carolina Companies 3
(Date:7/31/2014)... 31, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is looking at 10 tips to ... , “Addiction recovery is a lifelong process, and one that ... committed to without compromise,” commented Best Drug Rehabilitation’s CEO ...
(Date:7/31/2014)... The study, The Truth Behind ... episode of care payments for four clinical areas—congestive heart ... replacements (hips and knees). Using the definition of ... Care Improvement program, the study examines these clinical areas ... the country. , “Our study reaffirms that, in most ...
(Date:7/30/2014)... 30, 2014 The Mesothelioma ... Penn's Abramson Cancer Center, will host a regional ... experts in the field of mesothelioma. September 26 marks ... is open to the public, and specifically aimed at ... who have been exposed to asbestos. , The conference ...
(Date:7/30/2014)... returning National Guard soldiers were more likely to ... life setbacks, including job loss, legal problems, divorce, ... military families. Results of the study by researchers ... are published online in the American Journal ... a major concern for reservists returning home. Nearly ...
(Date:7/30/2014)... (PRWEB) July 31, 2014 “United States Orthopedic ... data on the United States Orthopedic Braces and Supports market. ... volume (in units) and average price data (in US dollars), ... Supports , Ankle Braces and Supports , ... Braces and Supports. , Orthotics is a specialty ...
Breaking Medicine News(10 mins):Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 3Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 3Health News:Vets' alcohol problems linked to stress on the home front 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 3Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 4
... released figures which show that there is an incredible ... for rehabilitation treatment programs under the banner of NHS(National ... . ,Most of the centers earmarked for drug ... the in- patient wards are empty and that referral ...
... floor spasm and pain, which may now be relieved by ... symptoms of this condition are heaviness, frequency or urgency in ... Abbott of the Royal Hospital For Women, Randwick conducted a ... effect of botox on women with pelvic spasms.30 women were ...
... Carnegie Mellon University conducted a path breaking study on ... in their ability to differentiate between living and non ... The paper which can be found in the Journal ... to one of the intriguing traits of autism: the ...
... The American College of Surgeons (ACS) has accredited NewYork-Presbyterian ... with the highest possible designation (1A),// in recognition of ... available. The top-level designation is a first for New ... ,An estimated 30 percent of U.S. adults 20 years ...
... a major recent countrywide study, antipsychotic drugs that are ... in treating Alzheimer's disease as most of the patients ... ,This study was conducted by Lon Schneider, professor ... the Keck School of Medicine of the University of ...
... develop pneumococcal pneumonia -- a common bacterial pneumonia that ... October issue of Mayo Clinic Women's HealthSource is spreading ... //against this form of pneumonia and reduces the serious ... unaware of the vaccine, or may not know that ...
Cached Medicine News:Health News:NHS De-addiction, Rehabilitation waiting time ticking into months 2Health News:Autistic Children May Lag behind in ‘Categorization of Objects 2Health News:NewYork-Presbyterian Receives Highest Accreditation for Bariatric Surgery 2
Desmarres Lid Retractor thin solid blades. Size 2....
... system introduces a new level ... microsurgical instrumentation. It has an ... with advanced microcomputer control of ... operate with a full range ...
Multiple Modulation Phaco (MMP) programmability with eight surgeon settings for maximum versatility. The combination of the peristaltic power balanced pump and the piezoelectric handpiece results in ...
... is a unique combination of Paradigm's ... flexibility for modular hardware modifications and ... of changing cataract surgical techniques and ... ophthalmic surgical platforms providing open architecture ...
Medicine Products: